• mail us help@24marketresearch.com
  • Int'l 1(332) 2424 294 (Int'l)

TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Pegfilgrastim Biosimilar Market Research Report 2025, Forecast to 2032

Global Pegfilgrastim Biosimilar Market Research Report 2025, Forecast to 2032

  • Category:Life Sciences
  • Published on : 16 December 2024
  • Pages :122
  • Formats:
  • Report Code:24MRES-8023809
Click for best price

Best Price: $2600

Report Overview

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The global Pegfilgrastim Biosimilar market size was estimated at USD 1522 million in 2023 and is projected to reach USD 2751.41 million by 2032, exhibiting a CAGR of 6.80% during the forecast period.

North America Pegfilgrastim Biosimilar market size was estimated at USD 444.17 million in 2023, at a CAGR of 5.83% during the forecast period of 2025 through 2032.

This report provides a deep insight into the global Pegfilgrastim Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pegfilgrastim Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Pegfilgrastim Biosimilar market in any manner.
Global Pegfilgrastim Biosimilar Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy

TABLE OF CONTENTS

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Pegfilgrastim Biosimilar
1.2 Key Market Segments
1.2.1 Pegfilgrastim Biosimilar Segment by Type
1.2.2 Pegfilgrastim Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Pegfilgrastim Biosimilar Market Overview
2.1 Global Market Overview
2.1.1 Global Pegfilgrastim Biosimilar Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Pegfilgrastim Biosimilar Market Competitive Landscape
3.1 Global Pegfilgrastim Biosimilar Sales by Manufacturers (2019-2025)
3.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Manufacturers (2019-2025)
3.3 Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pegfilgrastim Biosimilar Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Pegfilgrastim Biosimilar Sales Sites, Area Served, Product Type
3.6 Pegfilgrastim Biosimilar Market Competitive Situation and Trends
3.6.1 Pegfilgrastim Biosimilar Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pegfilgrastim Biosimilar Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Pegfilgrastim Biosimilar Industry Chain Analysis
4.1 Pegfilgrastim Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Pegfilgrastim Biosimilar Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Pegfilgrastim Biosimilar Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2019-2025)
6.3 Global Pegfilgrastim Biosimilar Market Size Market Share by Type (2019-2025)
6.4 Global Pegfilgrastim Biosimilar Price by Type (2019-2025)
7 Pegfilgrastim Biosimilar Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pegfilgrastim Biosimilar Market Sales by Application (2019-2025)
7.3 Global Pegfilgrastim Biosimilar Market Size (M USD) by Application (2019-2025)
7.4 Global Pegfilgrastim Biosimilar Sales Growth Rate by Application (2019-2025)
8 Pegfilgrastim Biosimilar Market Consumption by Region
8.1 Global Pegfilgrastim Biosimilar Sales by Region
8.1.1 Global Pegfilgrastim Biosimilar Sales by Region
8.1.2 Global Pegfilgrastim Biosimilar Sales Market Share by Region
8.2 North America
8.2.1 North America Pegfilgrastim Biosimilar Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pegfilgrastim Biosimilar Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pegfilgrastim Biosimilar Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pegfilgrastim Biosimilar Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pegfilgrastim Biosimilar Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Pegfilgrastim Biosimilar Market Production by Region
9.1 Global Production of Pegfilgrastim Biosimilar by Region (2019-2025)
9.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2019-2025)
9.3 Global Pegfilgrastim Biosimilar Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Pegfilgrastim Biosimilar Production
9.4.1 North America Pegfilgrastim Biosimilar Production Growth Rate (2019-2025)
9.4.2 North America Pegfilgrastim Biosimilar Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Pegfilgrastim Biosimilar Production
9.5.1 Europe Pegfilgrastim Biosimilar Production Growth Rate (2019-2025)
9.5.2 Europe Pegfilgrastim Biosimilar Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Pegfilgrastim Biosimilar Production (2019-2025)
9.6.1 Japan Pegfilgrastim Biosimilar Production Growth Rate (2019-2025)
9.6.2 Japan Pegfilgrastim Biosimilar Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Pegfilgrastim Biosimilar Production (2019-2025)
9.7.1 China Pegfilgrastim Biosimilar Production Growth Rate (2019-2025)
9.7.2 China Pegfilgrastim Biosimilar Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Novartis
10.1.1 Novartis Pegfilgrastim Biosimilar Basic Information
10.1.2 Novartis Pegfilgrastim Biosimilar Product Overview
10.1.3 Novartis Pegfilgrastim Biosimilar Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis Pegfilgrastim Biosimilar SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Mylan
10.2.1 Mylan Pegfilgrastim Biosimilar Basic Information
10.2.2 Mylan Pegfilgrastim Biosimilar Product Overview
10.2.3 Mylan Pegfilgrastim Biosimilar Product Market Performance
10.2.4 Mylan Business Overview
10.2.5 Mylan Pegfilgrastim Biosimilar SWOT Analysis
10.2.6 Mylan Recent Developments
10.3 Coherus BioSciences
10.3.1 Coherus BioSciences Pegfilgrastim Biosimilar Basic Information
10.3.2 Coherus BioSciences Pegfilgrastim Biosimilar Product Overview
10.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Product Market Performance
10.3.4 Coherus BioSciences Pegfilgrastim Biosimilar SWOT Analysis
10.3.5 Coherus BioSciences Business Overview
10.3.6 Coherus BioSciences Recent Developments
10.4 Mundipharma International
10.4.1 Mundipharma International Pegfilgrastim Biosimilar Basic Information
10.4.2 Mundipharma International Pegfilgrastim Biosimilar Product Overview
10.4.3 Mundipharma International Pegfilgrastim Biosimilar Product Market Performance
10.4.4 Mundipharma International Business Overview
10.4.5 Mundipharma International Recent Developments
10.5 Biocon
10.5.1 Biocon Pegfilgrastim Biosimilar Basic Information
10.5.2 Biocon Pegfilgrastim Biosimilar Product Overview
10.5.3 Biocon Pegfilgrastim Biosimilar Product Market Performance
10.5.4 Biocon Business Overview
10.5.5 Biocon Recent Developments
10.6 Intas Pharmaceuticals
10.6.1 Intas Pharmaceuticals Pegfilgrastim Biosimilar Basic Information
10.6.2 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Overview
10.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Market Performance
10.6.4 Intas Pharmaceuticals Business Overview
10.6.5 Intas Pharmaceuticals Recent Developments
10.7 Pfizer
10.7.1 Pfizer Pegfilgrastim Biosimilar Basic Information
10.7.2 Pfizer Pegfilgrastim Biosimilar Product Overview
10.7.3 Pfizer Pegfilgrastim Biosimilar Product Market Performance
10.7.4 Pfizer Business Overview
10.7.5 Pfizer Recent Developments
10.8 Dr Reddy

LIST OF TABLES & FIGURES

List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pegfilgrastim Biosimilar Market Size Comparison by Region (M USD)
Table 5. Global Pegfilgrastim Biosimilar Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Pegfilgrastim Biosimilar Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2022)
Table 10. Global Market Pegfilgrastim Biosimilar Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Pegfilgrastim Biosimilar Sales Sites and Area Served
Table 12. Manufacturers Pegfilgrastim Biosimilar Product Type
Table 13. Global Pegfilgrastim Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pegfilgrastim Biosimilar
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pegfilgrastim Biosimilar Market Challenges
Table 22. Global Pegfilgrastim Biosimilar Sales by Type (K MT)
Table 23. Global Pegfilgrastim Biosimilar Market Size by Type (M USD)
Table 24. Global Pegfilgrastim Biosimilar Sales (K MT) by Type (2019-2025)
Table 25. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2019-2025)
Table 26. Global Pegfilgrastim Biosimilar Market Size (M USD) by Type (2019-2025)
Table 27. Global Pegfilgrastim Biosimilar Market Size Share by Type (2019-2025)
Table 28. Global Pegfilgrastim Biosimilar Price (USD/MT) by Type (2019-2025)
Table 29. Global Pegfilgrastim Biosimilar Sales (K MT) by Application
Table 30. Global Pegfilgrastim Biosimilar Market Size by Application
Table 31. Global Pegfilgrastim Biosimilar Sales by Application (2019-2025) & (K MT)
Table 32. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2019-2025)
Table 33. Global Pegfilgrastim Biosimilar Sales by Application (2019-2025) & (M USD)
Table 34. Global Pegfilgrastim Biosimilar Market Share by Application (2019-2025)
Table 35. Global Pegfilgrastim Biosimilar Sales Growth Rate by Application (2019-2025)
Table 36. Global Pegfilgrastim Biosimilar Sales by Region (2019-2025) & (K MT)
Table 37. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2019-2025)
Table 38. North America Pegfilgrastim Biosimilar Sales by Country (2019-2025) & (K MT)
Table 39. Europe Pegfilgrastim Biosimilar Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Pegfilgrastim Biosimilar Sales by Region (2019-2025) & (K MT)
Table 41. South America Pegfilgrastim Biosimilar Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Pegfilgrastim Biosimilar Sales by Region (2019-2025) & (K MT)
Table 43. Global Pegfilgrastim Biosimilar Production (K MT) by Region (2019-2025)
Table 44. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2019-2025)
Table 46. Global Pegfilgrastim Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Pegfilgrastim Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Pegfilgrastim Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Pegfilgrastim Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Pegfilgrastim Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Novartis Pegfilgrastim Biosimilar Basic Information
Table 52. Novartis Pegfilgrastim Biosimilar Product Overview
Table 53. Novartis Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Novartis Business Overview
Table 55. Novartis Pegfilgrastim Biosimilar SWOT Analysis
Table 56. Novartis Recent Developments
Table 57. Mylan Pegfilgrastim Biosimilar Basic Information
Table 58. Mylan Pegfilgrastim Biosimilar Product Overview
Table 59. Mylan Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Mylan Business Overview
Table 61. Mylan Pegfilgrastim Biosimilar SWOT Analysis
Table 62. Mylan Recent Developments
Table 63. Coherus BioSciences Pegfilgrastim Biosimilar Basic Information
Table 64. Coherus BioSciences Pegfilgrastim Biosimilar Product Overview
Table 65. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Coherus BioSciences Pegfilgrastim Biosimilar SWOT Analysis
Table 67. Coherus BioSciences Business Overview
Table 68. Coherus BioSciences Recent Developments
Table 69. Mundipharma International Pegfilgrastim Biosimilar Basic Information
Table 70. Mundipharma International Pegfilgrastim Biosimilar Product Overview
Table 71. Mundipharma International Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Mundipharma International Business Overview
Table 73. Mundipharma International Recent Developments
Table 74. Biocon Pegfilgrastim Biosimilar Basic Information
Table 75. Biocon Pegfilgrastim Biosimilar Product Overview
Table 76. Biocon Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Biocon Business Overview
Table 78. Biocon Recent Developments
Table 79. Intas Pharmaceuticals Pegfilgrastim Biosimilar Basic Information
Table 80. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Overview
Table 81. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Intas Pharmaceuticals Business Overview
Table 83. Intas Pharmaceuticals Recent Developments
Table 84. Pfizer Pegfilgrastim Biosimilar Basic Information
Table 85. Pfizer Pegfilgrastim Biosimilar Product Overview
Table 86. Pfizer Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Pfizer Business Overview
Table 88. Pfizer Recent Developments
Table 89. Dr Reddy?s Laboratories Pegfilgrastim Biosimilar Basic Information
Table 90. Dr Reddy?s Laboratories Pegfilgrastim Biosimilar Product Overview
Table 91. Dr Reddy?s Laboratories Pegfilgrastim Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. Dr Reddy?s Laboratories Business Overview
Table 93. Dr Reddy?s Laboratories Recent Developments
Table 94. Global Pegfilgrastim Biosimilar Sales Forecast by Region (2025-2032) & (K MT)
Table 95. Global Pegfilgrastim Biosimilar Market Size Forecast by Region (2025-2032) & (M USD)
Table 96. North America Pegfilgrastim Biosimilar Sales Forecast by Country (2025-2032) & (K MT)
Table 97. North America Pegfilgrastim Biosimilar Market Size Forecast by Country (2025-2032) & (M USD)
Table 98. Europe Pegfilgrastim Biosimilar Sales Forecast by Country (2025-2032) & (K MT)
Table 99. Europe Pegfilgrastim Biosimilar Market Size Forecast by Country (2025-2032) & (M USD)
Table 100. Asia Pacific Pegfilgrastim Biosimilar Sales Forecast by Region (2025-2032) & (K MT)
Table 101. Asia Pacific Pegfilgrastim Biosimilar Market Size Forecast by Region (2025-2032) & (M USD)
Table 102. South America Pegfilgrastim Biosimilar Sales Forecast by Country (2025-2032) & (K MT)
Table 103. South America Pegfilgrastim Biosimilar Market Size Forecast by Country (2025-2032) & (M USD)
Table 104. Middle East and Africa Pegfilgrastim Biosimilar Consumption Forecast by Country (2025-2032) & (Units)
Table 105. Middle East and Africa Pegfilgrastim Biosimilar Market Size Forecast by Country (2025-2032) & (M USD)
Table 106. Global Pegfilgrastim Biosimilar Sales Forecast by Type (2025-2032) & (K MT)
Table 107. Global Pegfilgrastim Biosimilar Market Size Forecast by Type (2025-2032) & (M USD)
Table 108. Global Pegfilgrastim Biosimilar Price Forecast by Type (2025-2032) & (USD/MT)
Table 109. Global Pegfilgrastim Biosimilar Sales (K MT) Forecast by Application (2025-2032)
Table 110. Global Pegfilgrastim Biosimilar Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Pegfilgrastim Biosimilar
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pegfilgrastim Biosimilar Market Size (M USD), 2019-2032
Figure 5. Global Pegfilgrastim Biosimilar Market Size (M USD) (2019-2032)
Figure 6. Global Pegfilgrastim Biosimilar Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pegfilgrastim Biosimilar Market Size by Country (M USD)
Figure 11. Pegfilgrastim Biosimilar Sales Share by Manufacturers in 2023
Figure 12. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers in 2023
Figure 13. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pegfilgrastim Biosimilar Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pegfilgrastim Biosimilar Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pegfilgrastim Biosimilar Market Share by Type
Figure 18. Sales Market Share of Pegfilgrastim Biosimilar by Type (2019-2025)
Figure 19. Sales Market Share of Pegfilgrastim Biosimilar by Type in 2023
Figure 20. Market Size Share of Pegfilgrastim Biosimilar by Type (2019-2025)
Figure 21. Market Size Market Share of Pegfilgrastim Biosimilar by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pegfilgrastim Biosimilar Market Share by Application
Figure 24. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2019-2025)
Figure 25. Global Pegfilgrastim Biosimilar Sales Market Share by Application in 2023
Figure 26. Global Pegfilgrastim Biosimilar Market Share by Application (2019-2025)
Figure 27. Global Pegfilgrastim Biosimilar Market Share by Application in 2023
Figure 28. Global Pegfilgrastim Biosimilar Sales Growth Rate by Application (2019-2025)
Figure 29. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2019-2025)
Figure 30. North America Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Pegfilgrastim Biosimilar Sales Market Share by Country in 2023
Figure 32. U.S. Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Pegfilgrastim Biosimilar Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Pegfilgrastim Biosimilar Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Pegfilgrastim Biosimilar Sales Market Share by Country in 2023
Figure 37. Germany Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Pegfilgrastim Biosimilar Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Pegfilgrastim Biosimilar Sales Market Share by Region in 2023
Figure 44. China Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Pegfilgrastim Biosimilar Sales and Growth Rate (K MT)
Figure 50. South America Pegfilgrastim Biosimilar Sales Market Share by Country in 2023
Figure 51. Brazil Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Pegfilgrastim Biosimilar Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Pegfilgrastim Biosimilar Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Pegfilgrastim Biosimilar Production Market Share by Region (2019-2025)
Figure 62. North America Pegfilgrastim Biosimilar Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Pegfilgrastim Biosimilar Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Pegfilgrastim Biosimilar Production (K MT) Growth Rate (2019-2025)
Figure 65. China Pegfilgrastim Biosimilar Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Pegfilgrastim Biosimilar Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Pegfilgrastim Biosimilar Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Pegfilgrastim Biosimilar Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Pegfilgrastim Biosimilar Market Share Forecast by Type (2025-2032)
Figure 70. Global Pegfilgrastim Biosimilar Sales Forecast by Application (2025-2032)
Figure 71. Global Pegfilgrastim Biosimilar Market Share Forecast by Application (2025-2032)

SELECT A FORMAT

USD GBP EURO YEN Single User License
USD GBP EURO YEN Multi User License
USD GBP EURO YEN Corporate User License

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy
check discount